GSK (GSK LN) Q1 2026 (GBP) Adj. EPS 46.5p (exp. 43.2p), Turnover 7.63bln (prev. 7.51bln Y/Y), Gross Profit 1.87bln (prev. 1.93bln Y/Y); reaffirms 2026 guidance
Others:
- Speciality Medicines 3.2bln, Vaccines 2.1bln. Specialty Medicines +14% Y/Y; Respiratory, Immunology & Inflammation 0.9bln (+16%), Oncology 0.5bln (+28%), HIV 1.8bln (+10%).
- Vaccines +4% Y/Y; Shingrix 1.0bln (+20%), Meningitis vaccines 0.3bln (-3%), Arexvy 0.1bln (-18%).
Dividend:
- Q1 2026 dividend of 17p declared; 70p expected for full year 2026.
- GBP 1.7bln executed to date as part of the GBP 2bln share buyback programme announced at FY2024.
Guidance:
- Expect 2026 turnover growth of between 3% to 5%; Core operating profit growth of between 7% to 9%; Core EPS growth of between 7% to 9%.
- 2031 sales outlook of more than GBP 40bln.
Context
GSK's Q1 results exceeded EPS expectations, reflecting strong performance in Specialty Medicines and a stable turnover growth year-over-year. The reaffirmation of 2026 guidance suggests confidence in ongoing revenue expansion, particularly with a solid growth outlook and share buyback initiatives, which could positively influence sentiment among investors as they weigh long-term prospects.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#UNITED KINGDOM#EUROPE#GLAXOSMITHKLINE PLC#GSK.LN#IMPORTANT#EQUITIES#EU SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#FTSE 100 INDEX#GSK PLC#GSK#FTSE 100